Get in touch to find out more

Thank you for your submission!

Oops! Something went wrong while submitting the form.

Enabling Curative Cancer Treatment Through Early Detection.

Enabling curative cancer treatment through early detection

From Oxford to the world

Our journey started from the dreaming spires of Oxford. We are a multidisciplinary team with extensive expertise in cancer research, clinical medicine, machine learning and business on a mission to bring hope to cancer patients and their families worldwide

Learn about our team

Our innovation takes cancer detection to where no one has gone before

Learn about the science

January 10, 2023

Oxford Cancer Analytics Raises $3.7M Led by Eka Ventures to Revolutionize Liquid Biopsy and Early Cancer Detection

Oxford Cancer Analytics is pioneering a new generation of blood based liquid biopsy tests for early cancer detection, and has announced the completion of an additional seed financing round, led by Eka Ventures, with participation from LifeArc, MegaRobo Technologies, Oxford Technology Management, and value-add individual investors.

orange arrow pointing right

December 16, 2022

Oxford team aims to detect lung cancer early via a simple blood test

The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer.

orange arrow pointing right

October 20, 2021

OXFO Elevate Success Story Snippets: OXcan

Ahead of the OXFO annual Demo Day in November, they look at some of the success stories of our past-cohort ventures and how the Elevate accelerator has played a pivotal role in their growth. This snippet focuses on Oxford Cancer Analytics (OXcan), which was one of their portfolio ventures in cohort 3 in 2020.

orange arrow pointing right